- Stocks
- Healthcare
- NASDAQ: APLS

Price (delayed)

$39.53

Market cap

$4.8B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.45

Enterprise value

$4.58B

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims

The EPS is up by 45% year-on-year and by 22% since the previous quarter

APLS's net income is up by 40% year-on-year and by 21% since the previous quarter

The company's quick ratio has shrunk by 52% YoY but it rose by 22% QoQ

The equity has increased by 37% since the previous quarter but it has declined by 35% year-on-year

The company's gross margin fell by 2.3% YoY

What are the main financial stats of APLS

Market
Valuations
Earnings

Shares outstanding

121.37M

Market cap

$4.8B

Enterprise value

$4.58B

Price to earnings (P/E)

N/A

Price to book (P/B)

17.87

Price to sales (P/S)

9.27

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

8.74

Revenue

$524.07M

EBIT

-$386.23M

EBITDA

-$384.48M

Free cash flow

-$550.81M

Per share
Balance sheet
Liquidity

EPS

-$3.45

Free cash flow per share

-$4.48

Book value per share

$2.21

Revenue per share

$4.26

TBVPS

$6.77

Total assets

$831.93M

Total liabilities

$565.25M

Debt

$109.14M

Equity

$266.68M

Working capital

$596.14M

Debt to equity

0.41

Current ratio

3.77

Quick ratio

2.76

Net debt/EBITDA

0.57

Margins
Efficiency
Dividend

EBITDA margin

-73.4%

Gross margin

86.5%

Net margin

-79.6%

Operating margin

-77.1%

Return on assets

-49.8%

Return on equity

-160.7%

Return on invested capital

-126.5%

Return on capital employed

-62.6%

Return on sales

-73.7%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Apellis Pharmaceuticals stock price performed over time

Intraday

1.65%

1 week

9.08%

1 month

-6.99%

1 year

-53.5%

YTD

-33.96%

QTD

3.05%

How have Apellis Pharmaceuticals's revenue and profit performed over time

Revenue

$524.07M

Gross profit

$453.16M

Operating income

-$404.13M

Net income

-$417.27M

Gross margin

86.5%

Net margin

-79.6%

The company's net margin has surged by 88% YoY and by 40% QoQ

APLS's operating margin has surged by 87% year-on-year and by 41% since the previous quarter

APLS's net income is up by 40% year-on-year and by 21% since the previous quarter

APLS's operating income is up by 37% year-on-year and by 22% since the previous quarter

What is Apellis Pharmaceuticals's growth rate over time

What is Apellis Pharmaceuticals stock price valuation

P/E

N/A

P/B

17.87

P/S

9.27

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

8.74

The EPS is up by 45% year-on-year and by 22% since the previous quarter

The equity has increased by 37% since the previous quarter but it has declined by 35% year-on-year

The P/B is 37% less than the last 4 quarters average of 28.3 and 29% less than the 5-year quarterly average of 25.3

The stock's price to sales (P/S) is 65% less than its last 4 quarters average of 26.8

APLS's revenue is up by 32% since the previous quarter

How efficient is Apellis Pharmaceuticals business performance

The return on sales has surged by 88% year-on-year and by 41% since the previous quarter

The company's return on invested capital rose by 47% YoY and by 36% QoQ

APLS's ROA is up by 35% year-on-year and by 18% since the previous quarter

APLS's ROE is up by 29% YoY and by 10% QoQ

What is APLS's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for APLS.

How did Apellis Pharmaceuticals financials performed over time

Apellis Pharmaceuticals's total assets is 47% more than its total liabilities

The company's quick ratio has shrunk by 52% YoY but it rose by 22% QoQ

The company's current ratio fell by 45% YoY but it rose by 22% QoQ

The company's debt is 59% lower than its equity

The debt to equity has soared by 52% year-on-year but it has declined by 28% since the previous quarter

The equity has increased by 37% since the previous quarter but it has declined by 35% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.